Agenus shared a post on LinkedIn:
“Agenus applauds the FDA and Commissioner Marty Makary, M.D., M.P.H., for expanding the priority review voucher program to accelerate access to innovative, chemo-free, tumor-shrinking cancer therapies. This is an important first step in addressing the rising rates of colorectal cancer in America, and we remain committed to solving this challenge – together with our nation’s leaders, clinicians, researchers, and the broader medical community.
For the millions of people facing cancers with limited effective options – including the ~95%+ of metastatic colorectal cancer patients living with MSS disease that are still waiting for new options – this renewed focus on cancer innovation offers meaningful hope.
At ESMO25, Agenus presented compelling data from its BOT/BAL program showing durable survival and tumor regression across multiple ‘cold’ and checkpoint-refractory tumors, including MSS mCRC. We share the FDA’s vision for rapidly advancing therapies that meaningfully extend life without the burden of chemotherapy.”
More posts featuring Agenus.